{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-089871","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.161921+00:00","generated_at":"2026-05-15T21:45:31.141121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TScan Therapeutics Q4 net loss $23M; cash $152.4M; FDA clears TSC-102 INDs; plans Phase 3 trial Q2 2026","bullets":["Net loss $23.0M in Q4 2025 vs $35.8M Q4 2024; revenue $2.6M vs $0.7M.","Cash and equivalents $152.4M as of Dec 31, 2025; funds operations into H2 2027.","FDA cleared INDs for TSC-102-A01 and TSC-102-A03 targeting CD45 for heme malignancies post-HCT.","Enrollment completed in Cohort C of ALLOHA heme trial with commercial-ready manufacturing; initial data due Q2 2026.","Discontinued solid tumor PLEXI-T trial; advancing in vivo TCR-T engineering and autoimmunity programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-089871","json":"https://secwatch.observer/filing/0001193125-26-089871.json","markdown":"https://secwatch.observer/filing/0001193125-26-089871.md","text":"https://secwatch.observer/filing/0001193125-26-089871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526089871/0001193125-26-089871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526089871/tcrx-20260304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:45:31.141121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}